Article Details

AstraZeneca Shows Cardiovascular Ambition With Lipoprotein Disruptor Deal - Scrip

Retrieved on: 2024-10-07 16:16:43

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca Shows Cardiovascular Ambition With Lipoprotein Disruptor Deal - Scrip. View article details on hiswai:

Excerpt

The $100m upfront deal help AZ to fill out its cardiovascular, renal and metabolism portfolio, now joining Lilly in seeking to develop an oral ...

Article found on: scrip.citeline.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up